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“President Bush asked Congress for $7.1 billion to fund preparations, 
and in December 2005 Congress appropriated $3.8 billion to help the 
Nation prepare.  Of that, $3.3 billion was allocated to HHS. This report 
outlines how that funding is being used to help achieve HHS’s ﬁve 
primary objectives.”
We are in a race.  We are in a race against a fast moving virulent virus with the potential to cause an inﬂuenza pandemic.  In November when President 
Bush announced the National Strategy for Pandemic Inﬂuenza, the highly 
pathogenic H5N1 avian ﬂu virus was conﬁrmed in birds in 16 countries.  It was 
known to have infected 122 people and 62 – half of those infected – died.  
Today, four months later, H5N1 
has spread to 37 nations on 
three continents; 175 people 
have been infected and 96 
of them have died.  To date, 
most of those people were 
exposed to infected poultry.  
Fortunately, there has been no 
sustained human-to-human 
transmission of the disease, 
but the rapid spread of H5N1 
is reason for concern.  
We are in a race, a race 
against a quick changing 
virus, for H5N1 has not only spread, it has evolved.  There are now two main 
variants, or clades, of H5N1 and it is this second, newer clade that is spreading 
across western Asia into Europe, the Middle East and Africa.  This second clade 
has killed over 60 percent of those it is known to have infected.
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Countries with Avian Inﬂuenza and
Cumulative Human Deaths
Countries with avian inﬂuenza in animals
Human Deaths (cumulative)
2003       2004          2005  2006
         Through March 8
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Message from the Secretary
Flu Terms Defined
Seasonal (or Common) flu is a respiratory illness that
can be transmitted person to person. Most people have
some immunity, and a vaccine is available.
Avian (or bird) flu is caused by influenza viruses that
occur naturally among wild birds. The H5N1 variant is 
deadly to domestic fowl and can be transmitted from 
birds to humans. There is no human immunity and no
vaccine available.
Pandemic flu is virulent flu that causes a global
outbreak, or pandemic, of serious illness. Because there
is little immunity, the disease can be spread easily
from person to person. Currently, there is no pandemic
flu.
“Let me be clear. It is only 
a matter of time before we 
discover H5N1 in America. 
The migration patterns of the 
wild fowl that carry the virus 
make its appearance here 
almost inevitable.”
 –Secretary Michael Leavitt,   
HHS 
        Our Five Priorities
President Bush asked Congress for $7.1 billion to fund preparations, and in 
December 2005 Congress appropriated $3.8 billion to help the Nation prepare.  
Of that, $3.3 billion was allocated to HHS. This report outlines how that funding is 
being used to help achieve HHS’s ﬁve primary objectives.
•  Monitoring disease spread to support rapid response
•  Developing vaccines and vaccine production capacity
•  Stockpiling antivirals and other countermeasures
•  Coordinating federal, state and local preparation 
•  Enhancing outreach and communications planning
We are in a race, a race against time and complacency.  There is a role for 
everyone and we must count on everyone to fulﬁll their role. 
By deﬁnition a pandemic is deﬁned 
as a global event.  In reality, a 
pandemic is a local crisis worldwide.  
It can happen in every state and 
every city and every town at almost 
the same time.  
A pandemic is not like a hurricane or 
an earthquake, where resources and 
help can be shifted from one area 
to another. Should it occur, every 
community will need to rely on its 
own planning and its own resources 
as it ﬁghts the outbreak.
Preparation is a continuum. Each day 
we prepare brings us closer to being 
ready. We are better prepared today 
than we were yesterday. And we must be better prepared tomorrow than we are 
today.
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Message from the Secretary (continued)
Pandemic Influenza Plan Funding
2006 Appropriations: HHS Allocation ($3.3B)
(Dollars in Millions)
Vaccine
Antivirals
State & Local Preparedness
Medical Supplies
Other Domestic*
International Activities**
Risk Communications
$1,781
$731
$350
$162
$133
$125 $38
  *Other Domestic Includes:
    Surveillance, Quarantine, Lab Capacity, Rapid Tests
**International Activities Includes:
    International Preparedness, Surveillance, and
    Response
“We are better prepared 
today than we were 
yesterday. And we must be 
better prepared tomorrow 
than we are today.”
Our ﬁrst line of defense is early detection.  It is critical that we know immediately if the H5N1 inﬂuenza virus becomes capable of sustained 
human-to-human transmission.  Early detection will give us the opportunity 
to respond, to attempt containment and to quickly gain the virus samples 
necessary for the development of a true pandemic vaccine.
Early detection is a race against time.  Containing or slowing an inﬂuenza 
pandemic demands that a nascent outbreak anywhere in the world be 
recognized and conﬁrmed within 1 to 2 weeks.  
        International Collaboration and Monitoring
This is a big job.  For HHS, it means putting experts on the ground in numerous 
nations spread across a vast landscape. It means working shoulder to shoulder 
with our federal colleagues. 
Early detection requires international collaboration.  It means working closely 
with the World Health Organization (WHO), the United Nations Food and 
Agriculture Organization, the World Organisation for Animal Health, the Institute 
Pasteur, and numerous national governments.  Together, we are tracking the 
spread of the disease, conducting 
epidemiological studies of human 
infection, training local specialists and 
providing them with the tools for early 
and accurate detection.  
CDC and USAID will soon enter into an 
agreement with the Wildlife Conservation 
Society to provide additional monitoring. 
        Detection at Home
In February, the FDA approved a new 
laboratory test capable of diagnosing 
H5N1 inﬂuenza strains within four hours 
of receiving a sample.  The new test cuts 
days from the time needed to conﬁrm 
human infection.  FDA is also providing scientiﬁc and regulatory assistance to 
diagnostic manufacturers to speed the development and deployment of new 
detection products.  
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Monitoring and Surveillance
$258M
“For a couple of weeks, 
it was raining dead  
swans all over Europe.” 
 –Jan Slingenberg,   
UNFAO
As the avian infection moves closer to America, the Departments of Agriculture, 
Interior and Health and Human Services are stepping up the monitoring and 
testing of migratory birds.  This surveillance is essential to provide early warning 
so the disease does not spread to people, poultry and pets and to insure the 
safety of the nation’s food supply.
To monitor possible human infection, CDC is strengthening local laboratory 
capacity and capability, improving reporting systems and accelerating 
implementation of the national BioSense program, which collects real-time data 
from hospitals and other clinical-data sources.  
  
Vaccines
The best defense against inﬂuenza is vaccination.  It is also the most difﬁcult defense to achieve.  A fully effective vaccine cannot be developed until the 
virus strain it must protect against has evolved and been identiﬁed.  And once 
developed, there must be the production capacity to manufacture enough 
vaccine to protect the population.
HHS, through its National Institute of Allergy and Infectious 
Diseases (NIAID), is addressing the problem in a number 
of ways.  These include the development of pre-pandemic 
vaccines based on current lethal strains of H5N1 and 
collaboration with industry to increase the Nation’s vaccine 
production capacity, as well as seeking ways to expand or 
extend the existing supply.  We are also doing research in the 
development of new types of inﬂuenza vaccines.
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Monitoring and Surveillance (continued) 
At the International Pledging 
Conference on Avian and 
Human Inﬂuenza in Beijing 
in January 2006, the US 
committed $334 million 
in US grants and technical 
assistance to aid global effort. 
$1,781M
In early 2004, NIAID researchers applied a technology called reverse genetics to 
the H5N1 virus isolated from a patient in Vietnam to create an H5N1 reference 
vaccine strain.  Working with industry, NIAID was able to create an inactivated 
H5N1 virus vaccine for clinical testing.  In this testing, conducted in the summer 
of 2005, the vaccine induced an immune response predictive of protection 
against the H5N1 virus.  We then contracted with two companies to manufacture 
nearly 8 million doses of this vaccine for strategic stockpiling.
        Vaccine for a Changing Virus
However, all inﬂuenza viruses evolve, or “drift” genetically over time.  By 
2005/2006 winter the H5N1 strain had drifted enough to result in a second 
distinct strain of H5N1. This strain, also lethal, is now circulating in Europe, 
Africa and parts of Asia.  Its appearance dictates that we begin developing a 
second pre-pandemic vaccine. 
The CDC has already taken the ﬁrst step by producing the reference virus that 
will serve as a seed from which a second vaccine might be developed.  It is 
probable that H5N1 will continue to evolve, making it necessary 
to develop a series of vaccines.  There is simply no way to 
predict which strain, if any, might produce a virus capable of 
mass human-to-human transmission – or which vaccine will 
be most effective against it.  For this reason it is prudent to 
maintain stockpiles against each of the main circulating H5N1 
strains.
In March, FDA released draft guidance for clinical data that 
are needed to show safety and effectiveness for new seasonal 
and pandemic inﬂuenza vaccines.  The FDA also outlined an 
approach for an accelerated approval of these vaccines. 
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Vaccines (continued) 
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There is simply no way 
to predict which strain, if 
any, might produce a virus 
capable of mass human-to-
human transmission – or 
which vaccine will be most 
effective against it.  
The CDC has already taken 
the ﬁrst step by producing 
the reference virus that will 
serve as a seed from which 
a second vaccine might be 
developed.
Vaccines (continued) 
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        Increasing Vaccine Capacity 
The current U.S. capacity for manufacturing egg-based vaccines is not sufﬁcient 
to supply our entire population.  HHS is working with industry to determine ways 
to increase that capacity, including developing new facilities and expanding 
production in existing facilities.  A request for formal proposals will be issued in 
April 2006. 
The threat of liability has been a major obstacle to developing a strong domestic 
vaccine industry.  HHS worked with the Department of Justice and Congress 
to address the problem.  As a result, Congress adopted legislation (PREP Act) 
providing industry with limited liability when meeting a declared public health 
emergency.
Current egg-based vaccine manufacturing methods are complex, difﬁcult to 
expand rapidly to meet increased demand, and subject to failure if the vaccine 
strain does not grow efﬁciently in eggs.  HHS is supporting research into cell-
based vaccine manufacture, which holds the promise of a reliable, ﬂexible, and 
easily scalable method of producing vaccine domestically.  In April 
2005, HHS announced a $97 million contract for the development of 
cell-based ﬂu vaccine, and we expect to award additional contracts 
for developing cell-based vaccines this spring.
There is also research into ways to increase the effectiveness 
of vaccines by exploring antigen-sparing technologies such as 
adjuvants, substances that increase either the efﬁcacy or potency 
of a vaccine.  If successful, they extend a given supply of vaccine to 
protect more people.
If a pandemic occurs prior to licensure of a vaccine, the FDA can use its 
Emergency Use Authorization authority to permit the use of unapproved 
products (or to permit unapproved uses for previously approved products) if 
there’s a reasonable belief the products may be effective and if the beneﬁts 
would outweigh risks.
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Antivirals are drugs that lessen the impacts of ﬂu. There are currently two FDA-approved antivirals that have shown effectiveness against the H5N1 
virus, Tamiﬂu, and Relenza.  Both must be taken within 48 hours of the onset of 
ﬂu symptoms.  (Note that there are two other approved ﬂu antivirals, but CDC 
studies show H5N1 to be resistant to them.)
We are building a national stockpile of these two antivirals.  The immediate 
goal is to stockpile enough antivirals to treat 20 million people.  The longer-
term goal is to be able to treat 75 million people, or 25 percent of the U.S. 
population.  Achieving this goal depends on future pandemic ﬂu appropriations, 
manufacturing capacity and participation by the states.
        Antiviral Stockpiling
Because Tamiﬂu is also approved for prevention, treatment for an additional 
6 million people is also being stockpiled.  This will be used in an effort to help 
contain a ﬁrst outbreak of potential-pandemic inﬂuenza.  The concept is to 
blanket the area of the initial outbreak, giving Tamiﬂu to as many people as 
possible to prevent the ﬂu’s spread before it gets out of control.
In March, HHS purchased more than 14 million courses of Tamiﬂu and 
Relenza, which will increase the national inventory to nearly 20 million 
courses.  The total targeted stockpile is 81 million courses by the end of 
2008.  HHS will purchase 50 million out right and subsidize (by 25 percent) 
the states’ purchase of 31 million courses.  (A course is the number of 
doses needed to treat one person – ten capsules in the case of Tamiﬂu.) 
Antivirals will be distributed among the states and territories on a per-capita 
basis.
FDA is monitoring Tamiﬂu shipments to identify potential counterfeits, and 
is actively investigating companies selling fraudulent, unapproved inﬂuenza 
products.
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Antivirals
$731M
Antiviral Purchases
12/08    81 million courses
12/06    26 million courses
03/06    20 million courses*
* a course is the number of doses needed to treat one person.
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The immediate goal is to 
stockpile enough antivirals 
to treat 20 million people.  
The longer-term goal is to 
be able to treat 75 million 
people, or 25 percent of 
the U.S. population. 
        New Antivirals Needed
Inﬂuenza viruses can develop resistance to antivirals over time.  New antivirals  
will be needed in the event H5N1 develops resistance to Tamiﬂu or Relenza. We 
are committing $200 million to the development of additional antivirals.  HHS 
expects to request formal proposals later this spring and to award contracts for 
the advanced development of promising antivirals by September 2006.
It is not enough to stockpile antivirals; there needs to be a plan to distribute 
them.  HHS is discussing with the states whether the antivirals should be centrally 
located or warehoused locally.  To receive funding, states are being required 
to develop distribution plans now, so that if a pandemic erupts, it will be clear 
where the drugs are to go and how they will get there.  In addition to stockpiling 
antivirals, $162 million will be used to procure essential medical supplies for 
a pandemic. Planned purchases this year include 6000 ventilators, 50 million 
surgical masks, 50 million N95 respirators, and face shields, gloves and gowns.
State and Local Preparedness
State and local preparedness is the foundation of pandemic readiness.   The challenges that we will face in a pandemic will be vastly different from 
other response situations.  An inﬂuenza pandemic is likely to occur almost 
simultaneously across countries and communities.  It will demand that every 
aspect of our communities be self-sufﬁcient, able to deal with the outbreak of 
illness should it hit.  Political leaders, employers, school leaders, healthcare 
leaders, faith-based and community organizations, families and the media must 
all be informed, engaged, and actively involved. 
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Antivirals (continued)
We are committing 
$200 million to 
the development of 
additional antivirals.
$350M
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To that end, President Bush directed and we convened a state and local 
preparedness process. We are working to help states, tribes, cities, schools, 
businesses, churches, and families throughout our nation plan for these unique 
challenges.   We are collaborating with governors’ ofﬁces in every state to hold 
pandemic planning summits and exercises.   To date, we have completed 23 
summits and planned an additional 20: we expect to visit the remaining states 
and territories this spring (see map).  I am hearing from governors and local 
ofﬁcials that the summits are helpful, and the process is working.  
Congress allocated $350 million this year to assist local and state preparedness. 
We are awarding $100 million to states right now. The remaining $250 million will 
be distributed later according to benchmarks we establish to measure progress.  
I am asking governors to make sure that their pandemic inﬂuenza plans are an 
integral element of and coordinate effectively with the National Response Plan 
and the National Incident Management System. 
I am asking them to establish a Pandemic Preparedness 
Coordinating Committee that represents all relevant 
stakeholders in their jurisdiction.  These collaborative 
committees will help states to articulate strategic priorities 
and oversee the development and execution of operational 
pandemic plans. 
One of the most important elements of the preparedness 
response is practicing.  We are assisting states in the 
development and administration of tabletop exercises to 
improve our Nation’s readiness to respond and recover from 
a pandemic. We are asking states to exercise their plans 
by the end of 2006, and will invite them to participate in a 
nationwide pandemic planning exercise within the next twelve 
months.  These planning and response exercises will help public health and law 
enforcement ofﬁcials establish procedures and locations for quarantine, surge 
capacity, diagnostics, communication and many other pandemic-related needs.  
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West Virginia is holding 
seven Regional Pandemic 
Flu Summits across 
their state to plan for the 
possibility of pandemic 
ﬂu and speciﬁc WV 
preparedness needs – this is 
a direct outcome of HHS/
WV summit held there in 
January.
State and Local Preparedness (continued)
HHS Pandemic Planning - State Summit Overview
23 Completed Summits 20 Scheduled Summits 7 Unscheduled Summits 
Including Puerto Rico and the Virgin Islands
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        Outreach Resources
During the 1918 inﬂuenza pandemic it was the newspapers and word of mouth 
that carried the news and information.  Today the media and web will be our 
primary pre-pandemic and pandemic communication sources.  Both must be 
used responsibly to inform and educate — to help achieve a nation prepared, 
but not in panic.
Today the media 
and web will be our 
primary pre-pandemic 
and pandemic 
communication 
sources. 
Communications 
Communications and outreach are essential to preparedness.  I am committed to telling people what we know when we know it; to inform the 
public without raising unnecessary alarm, and to collaborate with our public and 
private partners in a way that is fully transparent.  It is my hope that every state 
and local partner will practice that principle as well — every person must be a 
communicator.  
We must all be ready to provide the best instructions and advice on what is 
happening, status of school, business and transportation impacts, home health 
care practices and basic infection control. 
Congress foresaw the role and value of communications and funded our efforts 
to further develop comprehensive science-based risk communication strategies 
for pandemic inﬂuenza — communications that will touch every part of our 
nation with medical, social and economic implications and information on avian 
and pandemic inﬂuenza.   
Checklists to aid in pandemic inﬂuenza preparations have been developed by 
CDC.  These planning checklists provide speciﬁc 
guidance for state and local planning, businesses, 
health care providers, community organizations and 
individuals and families.  Other checklists are being 
developed, along with toolkits that provide more 
speciﬁc guidance.
The global nature of pandemic preparedness and the 
enormity of potential impacts are fostering a spirit 
of collaboration across the world.  Common efforts 
include surveillance of the disease, planning across 
national boundaries and economic sectors, and 
sharing research and technology. The U.S. and world 
organizations are conducting tabletop exercises and 
participating in international risk communications 
workshops and conferences at many levels.
Available Checklists:
� State and Local
� Individuals and Families
� Business
� Schools (K-12)
� Faith-based and Community Organizations
�Medical Offices and Clinics
� Home Health Services
Upcoming Checklists:
� Emergency Medical Services
� Preschool
� Colleges and Universities
� Long Term Care
� Travel Industry
� Transportation
$38M
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President Bush directed all federal agencies to establish a single, 
comprehensive web site to be the ofﬁcial federal source of pandemic and avian 
ﬂu information. This web site, www.PandemicFlu.gov, hosts a vast array of 
information designed to meet diverse audience needs.  It links to specialized 
information from federal agencies, states, international organizations and other 
important resources.  
New broadcast capabilities will allow us to reach media outlets more quickly and 
ultimately provide information directly to the public via satellite.  Convergence 
technologies will be used to 
integrate audio and video 
production on the web.  Video, 
audio, multi-media and print 
materials are being developed for 
broad dissemination.  Selected 
materials will be translated as 
appropriate.   
We are working to communicate 
to all the peoples of the world the 
essential information they need to 
plan, prepare and ultimately cope 
with pandemic ﬂu and its impacts.  
Communications (continued)
